Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Merck
McKesson
Colorcon
Healthtrust
AstraZeneca
Accenture
Queensland Health
Julphar
Fish and Richardson
Argus Health

Generated: January 22, 2018

DrugPatentWatch Database Preview

HUMALOG PEN Drug Profile

« Back to Dashboard

When do Humalog Pen patents expire, and what generic alternatives are available?

Humalog Pen is a drug marketed by Lilly and is included in one NDA.

The generic ingredient in HUMALOG PEN is insulin lispro recombinant. There are thirty-nine drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the insulin lispro recombinant profile page.
Summary for HUMALOG PEN
Drug patent expirations by year for HUMALOG PEN
Pharmacology for HUMALOG PEN
Ingredient-typeInsulin
Drug ClassInsulin Analog
Medical Subject Heading (MeSH) Categories for HUMALOG PEN

US Patents and Regulatory Information for HUMALOG PEN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Lilly HUMALOG PEN insulin lispro recombinant INJECTABLE;INJECTION 020563-002 Aug 6, 1998 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for HUMALOG PEN

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Lilly HUMALOG PEN insulin lispro recombinant INJECTABLE;INJECTION 020563-002 Aug 6, 1998 ➤ Subscribe ➤ Subscribe
Lilly HUMALOG PEN insulin lispro recombinant INJECTABLE;INJECTION 020563-002 Aug 6, 1998 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Boehringer Ingelheim
Cantor Fitzgerald
Queensland Health
Daiichi Sankyo
Healthtrust
Mallinckrodt
Deloitte
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot